🔎 Trials Near Me

Beranda › Kanker Paru › Nebraska

Uji klinis Kanker Paru di Nebraska

19 studi untuk Kanker Paru mencari peserta di lokasi di Nebraska.

Kota di Nebraska

Teks studi resmi (Bahasa Inggris)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Nebraska Medicine-Bellevue, Bellevue
  • Fred and Pamela Buffett Cancer Center - Kearney, Kearney
  • CHI Health Good Samaritan, Kearney
  • dan 5 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04267848

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • CHI Health Saint Francis, Grand Island
  • CHI Health Good Samaritan, Kearney
  • Alegent Health Immanuel Medical Center, Omaha
  • dan 2 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • Cancer Partners of Nebraska, Lincoln
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT04181060

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • NHO Revive Research Institute, LLC, Lincoln
  • NHO Support Center, Lincoln
  • Cancer Partners of Nebraska, Lincoln
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07222566

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  • Cancer Partners of Nebraska, Lincoln
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07489066

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Fremont, Fremont
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island, Grand Island
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional, Grand Island
  • dan 5 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06758401

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07063745

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • Research Site, Omaha
Menerima pesertaFase 2
Usia 18 hingga 95 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05061550

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC), Hastings
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06712316

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  • Nebraska Hematology-Oncology (NHO), Lincoln
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06712355

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
  • Nebraska Methodist Hospital, Omaha
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05624996

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Nebraska Cancer Specialists, Omaha
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT04198766

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

  • University of Nebraska Medical Center, Omaha
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT05242965

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Nebraska Cancer Specialist, Grand Island
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT06162221

Integrated Cancer Repository for Cancer Research

  • Mary Lanning Healthcare, Morrison Cancer Center, Hastings
  • Faith Regional Health Services, Carson Cancer Center, Norfolk
  • Great Plains Regional Medical Center, North Platte
  • dan 3 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • University of Nebraska Medical Center, Omaha
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 26 Jun 2026 · NCT04614103

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

  • Nebraska Cancer Specialists, Omaha
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT06922591

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Omaha
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.